Progenics Pharmaceuticals Inc (PGNX):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Progenics Pharmaceuticals Inc (PGNX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9946
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:53
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Progenics Pharmaceuticals Inc (Progenics) is a late-stage biopharmaceutical company that focuses on developing medicines and products for the treatment of cancer and related conditions. Its only commercial product, Relistor, is used for the treatment of opioid-induced constipation. The company’s pipeline comprises therapeutic agents that are designed to target cancer; PSMA-targeted imaging agents for prostate cancer that enable clinicians and patients to visualize and manage their disease; and a phase III candidate for the treatment of HIV. Progenics also offers bone scan index product EXINI Bone BSI tool and is approved for use in Europe, Japan and the US. The company markets Relistor, through a licensing agreement with Salix Pharmaceuticals outside the US except Japan. Progenics is headquartered in New York, the US.

Progenics Pharmaceuticals Inc (PGNX) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Progenics Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Progenics Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Progenics Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Progenics Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Progenics Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10
Progenics Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Progenics Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
MedImmune Enters Into Licensing Agreement With Progenics Pharma For Clostridium Difficile Preclinical Program 12
Exini Diagnostics Enters into Agreement with DexTech Medical for OsteoDex 13
Licensing Agreements 14
Progenics Pharma Enters into Licensing Agreement with Selexis 14
Bayer Enters into Licensing Agreement with Progenics Pharma 15
Progenics Pharmaceuticals Enters into Licensing Agreement with Johns Hopkins University 16
Molecular Insight Pharma Enters into Licensing Agreement with University of Zurich and Paul Scherrer Institute 17
ITM Isotopen Enters Into Licensing Agreement With Progenics Pharma For Dotatoc 18
Equity Offering 19
Progenics Pharma Plans to Raise up to USD75 Million in Public Offering of Shares 19
Progenics Pharma Prices Public Offering of Shares for USD75 Million 20
Progenics Pharma Completes Public Offering Of Shares For US$35 Million 22
Progenics Pharma Completes Public Offering Of Shares For US$37 Million 23
Progenics Pharma Completes Public Offering Of Common Stock For US$25 Million 24
Asset Transactions 26
CytoDyn Completes Acquisition Of PRO 140 From Progenics Pharma 26
Acquisition 28
Progenics Pharma Acquires Molecular Insight Pharma for up to USD106 Million 28
Progenics Pharmaceuticals Inc – Key Competitors 30
Progenics Pharmaceuticals Inc – Key Employees 31
Progenics Pharmaceuticals Inc – Locations And Subsidiaries 32
Head Office 32
Other Locations & Subsidiaries 32
Recent Developments 33
Financial Announcements 33
Jul 31, 2018: Azedra’s approval, progenics pharmaceuticals announces second quarter 2018 financial results and business update 33
May 09, 2018: Progenics Pharmaceuticals Announces First Quarter 2018 Financial Results and Business Update 36
Mar 08, 2018: Progenics Pharmaceuticals Announces Fourth Quarter and Full-Year 2017 Financial Results and Business Update 38
Nov 02, 2017: Progenics Pharmaceuticals Announces Third Quarter 2017 Financial Results and Business Update 40
Aug 09, 2017: Progenics Pharmaceuticals Announces Second Quarter 2017 Financial Results and Business Update 42
May 04, 2017: Progenics Pharmaceuticals Announces First Quarter 2017 Financial Results and Business Update 44
Mar 09, 2017: Progenics Pharmaceuticals Announces Fourth Quarter and Full-Year 2016 Financial Results and Business Update 46
Clinical Trials 48
Dec 06, 2017: First gastroenteropancreatic-neuroendocrine tumor (GEP-NET) patient in Europe for the COMPETE phase III clinical trial with n.c.a. 177Lu-Edotreotide (Solucin) 48
Nov 14, 2017: Successful Hosting of the Investigator Meeting for Phase III Clinical Trial COMPETE with n.c.a. 177Lu-Edotreotide (Solucin) in Cancer Patients with GEP-NET 50
Feb 14, 2017: Progenics Pharmaceuticals Announces Initiation of a Phase 1 Clinical Trial of its PSMA-Targeted Therapeutic Candidate 1095 For the Treatment of Metastatic Prostate Cancer 52
Appendix 53
Methodology 53
About GlobalData 53
Contact Us 53
Disclaimer 53

List of Tables
Progenics Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Progenics Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Progenics Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Progenics Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Progenics Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Progenics Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10
Progenics Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
MedImmune Enters Into Licensing Agreement With Progenics Pharma For Clostridium Difficile Preclinical Program 12
Exini Diagnostics Enters into Agreement with DexTech Medical for OsteoDex 13
Progenics Pharma Enters into Licensing Agreement with Selexis 14
Bayer Enters into Licensing Agreement with Progenics Pharma 15
Progenics Pharmaceuticals Enters into Licensing Agreement with Johns Hopkins University 16
Molecular Insight Pharma Enters into Licensing Agreement with University of Zurich and Paul Scherrer Institute 17
ITM Isotopen Enters Into Licensing Agreement With Progenics Pharma For Dotatoc 18
Progenics Pharma Plans to Raise up to USD75 Million in Public Offering of Shares 19
Progenics Pharma Prices Public Offering of Shares for USD75 Million 20
Progenics Pharma Completes Public Offering Of Shares For US$35 Million 22
Progenics Pharma Completes Public Offering Of Shares For US$37 Million 23
Progenics Pharma Completes Public Offering Of Common Stock For US$25 Million 24
CytoDyn Completes Acquisition Of PRO 140 From Progenics Pharma 26
Progenics Pharma Acquires Molecular Insight Pharma for up to USD106 Million 28
Progenics Pharmaceuticals Inc, Key Competitors 30
Progenics Pharmaceuticals Inc, Key Employees 31
Progenics Pharmaceuticals Inc, Subsidiaries 32

List of Figures
Progenics Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Progenics Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Progenics Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Progenics Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Progenics Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Progenics Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Progenics Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Progenics Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Progenics Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[Progenics Pharmaceuticals Inc (PGNX):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Rubis SCA (RUI):企業の財務・戦略的SWOT分析
    Rubis SCA (RUI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • Navamedic ASA (NAVA):企業の財務・戦略的SWOT分析
    Navamedic ASA (NAVA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Presence Health:企業の戦略的SWOT分析
    Presence Health - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servic …
  • MAX Resource Corp. (MXR):企業の財務・戦略的SWOT分析
    MAX Resource Corp. (MXR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Yapi Merkezi Holding Inc.:企業の戦略・SWOT・財務分析
    Yapi Merkezi Holding Inc. - Strategy, SWOT and Corporate Finance Report Summary Yapi Merkezi Holding Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • China National Petroleum Corporation:企業の戦略・SWOT・財務情報
    China National Petroleum Corporation - Strategy, SWOT and Corporate Finance Report Summary China National Petroleum Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysi …
  • RTI Surgical Inc (RTIX)-医療機器分野:企業M&A・提携分析
    Summary RTI Surgical Inc (RTI), formerly RTI Biologics Inc is a surgical implant company that offers biologic, metal and synthetic implants. The company’s products include spine implants, surgical specialties, sports medicine implants, cardiothoracic and orthobiologics. It offers spine implants such …
  • CeoTronics AG (CEK):企業の財務・戦略的SWOT分析
    CeoTronics AG (CEK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • PT Jasa Marga (Persero) Tbk:企業の戦略・SWOT・財務情報
    PT Jasa Marga (Persero) Tbk - Strategy, SWOT and Corporate Finance Report Summary PT Jasa Marga (Persero) Tbk - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Adani Enterprises Ltd (ADANIENT):企業の財務・戦略的SWOT分析
    Adani Enterprises Ltd (ADANIENT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Compania Minera Autlan SAB de CV:企業の戦略・SWOT・財務情報
    Compania Minera Autlan SAB de CV - Strategy, SWOT and Corporate Finance Report Summary Compania Minera Autlan SAB de CV - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • Kronos Worldwide Inc (KRO):企業の財務・戦略的SWOT分析
    Kronos Worldwide Inc (KRO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Life Time Inc:企業の戦略的SWOT分析
    Life Time Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services …
  • Bulgarian Telecommunications Company (VIVACOM):企業の戦略的SWOT分析
    Bulgarian Telecommunications Company (VIVACOM) - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitor …
  • AiVita Biomedical Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary AiVita Biomedical Inc (AiVita) is a biotechnology company developing novel stem cell technologies to develop cell-based treatments and healthcare products for the treatment of cancer, vision loss, and skincare formulations. Its lead therapeutic candidate is a patient-specific immunotherapy f …
  • William Hill PLC:企業の戦略・SWOT・財務分析
    William Hill PLC - Strategy, SWOT and Corporate Finance Report Summary William Hill PLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Grid2020, Inc.:電力:M&Aディール及び事業提携情報
    Summary Grid2020, Inc. (Grid2020) is a provider of smart grid solutions. The company offers an integrated distribution transformer monitoring solutions under the brand Optanode. The Optanode product family consists of sensors and smart analytics software and provides information about the distributi …
  • WS Atkins Plc:戦略・SWOT・企業財務分析
    WS Atkins Plc - Strategy, SWOT and Corporate Finance Report Summary WS Atkins Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Lam Research Corp (LRCX):企業の財務・戦略的SWOT分析
    Lam Research Corp (LRCX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Eurobio Scientific SA (ALERS):企業の製品パイプライン分析
    Summary Eurobio Scientific SA (Eurobio), formerly Diaxonhit SA, a subsidiary of Hellenic Petroleum SA, is a biotechnology company that provides diagnostic products. The company provides products such as TQS, used in treatment of teanus and BJI InoPlex, used for the treatment of prosthetic infection. …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆